{
  "abstract": "Genetic engineering has fundamentally transformed T cell–based therapies by enabling tumor targeting capability, improving their functionality, and facilitating allogeneic use. These strategies—originally developed in αβ chimeric antigen receptor (CAR)-T cells—have become increasingly established as blueprints for enhancing the function of other immune effector cells, including gamma delta (γδ) T cells. A recent study by Nishimoto et al showcased the adaptation of these engineering approaches to Vδ1 γδ T cells (ADI-270) by coexpressing a CD70-targeted CAR and a dominant-negative TGFβRII receptor (dnTGFβRII) to target CD70+ malignancies, addressing immunosuppression and host-versus-graft rejection. This commentary explores αβ T cell-derived engineering strategies applicable to γδ T cells, while also highlighting genome-editing innovations poised to advance next-generation γδ CAR-T development.",
  "authors": [
    {
      "affiliations": [
        "Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA"
      ],
      "name": "Wenlong Liu"
    },
    {
      "affiliations": [
        "Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA",
        "University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA",
        "University of Minnesota Center for Genome Engineering, Minneapolis, Minnesota, USA"
      ],
      "name": "Branden S Moriarity"
    },
    {
      "affiliations": [
        "Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA",
        "University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA",
        "University of Minnesota Center for Genome Engineering, Minneapolis, Minnesota, USA"
      ],
      "name": "Beau R Webber"
    }
  ],
  "title": "Genetic engineering and allogeneic optimization of Vδ1 γδ CAR-T cells (ADI-270) for cancer immunotherapy",
  "uid": "0792ec04-7075-5359-aaca-f2baf999829c"
}